Radiation for Lung Cancer: 264 Real Stories

264 stories match lung cancer and radiation. 187 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV Mucinous Lung Cancer Treated With Afatinib and Surgery

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: CD74-NRG1 fusion; ALK/ROS1/EGFR/BRAF/KRAS/MET/HER2 wild type; PD-L1 initially not expressed and later 0%-20%

Metastatic Site: bilateral lungs|bone|right adrenal gland

She was alive and receiving treatment after bone and right-adrenal progression at the latest follow-up.

PubMed Central
OutcomeCare Ongoing
Deborah, who was diagnosed with Stage I Lung CancerLung Cancer

Stage I Lung Cancer: Deborah's Patient Story

Patient Info: Deborah Schroeder, Female | Stage I

As of December 2020, Deborah had completed 3 separate 4-day SBRT courses for Stage I lung cancers and remained under monitoring for about 10 tiny lung nodules that had been stable for years.

MD Anderson
OutcomeCare Ongoing
Saila, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Saila's Patient Story

Patient Info: Saila Hanninen, Under 40 | Stage IV

Biomarkers: EGFR mutation

After progression on earlier EGFR-directed treatment and other therapies, Saila began chemotherapy and her cancer was stable at the time of the story.

Dana-Farber
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lung adenocarcinoma first presented through skin and haemorrhagic brain metastases

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: TTF-1-positive; CK7-positive; CEA-positive; PD-L1 10%; EGFR-negative; ALK-negative; ROS1-negative; BRAF-negative

Metastatic Site: skin|brain

Her condition declined rapidly after brain radiation, systemic therapy could not be started, and she died from metastatic lung cancer within 6 weeks of presentation.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Metastatic Lung Cancer Responded Completely After a Change in Immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: TTF-1-positive; napsin-positive; PD-L1 0%; high tumour mutational burden; no actionable mutations

Metastatic Site: bone (left iliac bone, acetabulum and thoracic…

After progression on nivolumab, atezolizumab produced a complete response by the 6-month scan; after 35 cycles, the response remained sustained, he was alive and well, and no immune-related adverse effects were documented.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Small Cell Lung Cancer With Unusual Colon Metastases After Afatinib

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: EGFR exon 19 deletion

Metastatic Site: liver|adrenal glands|bone|brain|ascending…

The cancer progressed after an initial response to afatinib, with new brain and colon metastases. She died from respiratory failure on August 1, 2016.

PubMed Central
OutcomeIn Memory
Tomma, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV Non-Small Cell Lung Cancer: Tomma's Patient Story

Patient Info: Tomma Hargraves, Female | Stage IV

Metastatic Site: brain

After a later brain and lymph-node relapse was brought under control, Tomma had no further cancer treatment and remained active in survivorship advocacy. She died on September 7, 2023.

AACR
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

More than 10 years living with relapsing extensive-stage small cell lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Chromogranin-positive.

Metastatic Site: pleura; pancreas; left kidney and perinephric region

After five treatment lines and several metastatic relapses over more than 10 years, his latest irinotecan and carboplatin course produced another partial response and he was doing well at the last follow-up.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Small cell lung cancer found through a disabling paraneoplastic neuropathy

Patient Info: Anonymized, Female, 60s

Biomarkers: Anti-CRMP5 antibody-positive.

She completed chemotherapy and radiation and entered oncology follow-up, while the disabling sensory and motor neuropathy persisted and rehabilitation continued.

PubMed Central
OutcomeCare Ongoing
Keith, who was diagnosed with Lung CancerLung Cancer

Lung Cancer: Keith's Survivor Story

Patient Info: Keith Medovich, Male, 60s

As of January 2020, Keith was rid of lung cancer after 2003 chemotherapy and radiation, but required ongoing management of severe late radiation-related airway stenosis with a custom patient-specific stent.

Cleveland Clinic
OutcomeCancer-Free / NED
Sara, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV RET Non-Small Cell Lung Cancer: Sara's Patient Story

Patient Info: Sara Whitlock, Female, 40s | Stage IV

Biomarkers: RET fusion-positive NSCLC

Metastatic Site: Brain; abdomen; bowel

As of November 2019, Sara had Stage IV RET fusion-positive NSCLC with a long-term response and no signs of cancer while taking selpercatinib/LOXO-292 on a clinical trial, with ongoing monthly follow-up.

Cleveland Clinic
OutcomeCare Ongoing
James, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ALK Non-Small Cell Lung Cancer: James's Patient Story

Patient Info: James “Rocky” Lagno, Male | Stage IV

Biomarkers: ALK-positive

Metastatic Site: brain

After starting ceritinib through compassionate use, Rocky reported stable disease from the middle of 2013 with quality of life close to his pre-diagnosis level, while recognizing that he was not in remission or cancer-free.

AACR
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Osimertinib Improved Spinal Cord Metastases in Long-Standing Lung Cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Initial surgical specimen: no detected EGFR mutation and ALK-negative. Later pleural-fluid tumor: acquired EGFR T790M mutation with no other detected EGFR mutation.

Metastatic Site: cervical and mediastinal lymph nodes; bone; brain;…

Osimertinib improved neurologic function and kept the lung cancer stable for 14 months; he later died from bacterial pneumonia.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Rapidly Progressive Stage IV Lung Adenocarcinoma With a Miliary Imaging Pattern

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: TTF-1-positive; p40-negative; chromogranin-negative; synaptophysin-negative; EGFR-negative; ALK-negative; ROS1-negative; PD-L1 expression 5%–10%.

The cancer progressed rapidly, and he died approximately four months after diagnosis while being transported to inpatient hospice.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Hormone Problems During Nivolumab Treatment for Advanced Lung Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR/ALK/ROS1/BRAF wild type

Metastatic Site: abdominal wall|brain

She was living with Stage IVA lung cancer after about 1 year of nivolumab. Thyroid levels normalized after levothyroxine adjustment, and continued endocrine monitoring was planned for treatment-related pituitary dysfunction.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Lung Cancer Treatment Complicated by Atezolizumab-Related Pneumonitis

Patient Info: Anonymized, Male, 70+

Biomarkers: EGFR mutation not detected; BRAF mutation not detected; ALK rearrangement not detected

The cancer progressed after chemoradiation. Atezolizumab was stopped because of pneumonitis, and he later began pemetrexed after a right adrenal mass became highly suspicious for malignancy.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Durable brain and leptomeningeal response to pembrolizumab in Stage IV lung cancer

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: PD-L1 high positive; EGFR negative; BRAF negative; KRAS negative; ROS1 negative; ALK negative

Metastatic Site: right adrenal gland, left sixth rib, brain,…

After 29 pembrolizumab cycles over 20 months, imaging showed no leptomeningeal disease, resolution of 3 brain lesions and marked reduction of the dominant frontal lesion; she remained neurologically intact and radiographically stable.

PubMed Central
OutcomeResponding Well
Cynthia, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Cynthia's Patient Story

Patient Info: Cynthia Hess, Female | Stage IV

Metastatic Site: Spine

As of October 2018, Cynthia’s spine metastasis had stopped growing after one stereotactic spinal radiosurgery treatment, her neck pain had subsided and future MRI scans were planned for monitoring.

Cleveland Clinic
OutcomeCare Ongoing